Redhill Biopharma (RDHL)

Take Impact Assessment

Impact Scorecard
About

Overall impact

B (67)

Commentary

Redhill Biopharma is a strong overall performer. With a 'B' rating of 67.0 for overall impact (77th percentile compared to all companies), Redhill Biopharma ranks 322nd out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 318 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 260 others. On top material causes for Redhill Biopharma's industry (Pharmaceuticals & Biotech), Redhill Biopharma performs well in Access to Affordable Healthcare (87.6 score), Disease Eradication (96.4), Technology Innovation (95.2) and 1 other cause where it received an 'A' score and performs poorly in Disaster Readiness and Effective Aid (34.8 score), Accountable Institutions (16.2) and Reduced Use of tobacco (38.3).

... read full commentary

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact

Cause			RDHL

Peer rank

Overall impact

Log in to view this information

Screens

Advertising
Alcohol
Alcohol - responsible marketing
Animal treatment
Anti-abortion support
Anti-Israel
Anti-personnel mines
Arctic drilling
Banned pesticides and chemicals
Biological and chemical weapons
Cannabis
Carbon emissions intensity
Child safety
Cluster munitions
Coal
Contraceptives
Controversial weapons
Deforestation - financing
Deforestation - supply chain
Depleted uranium
Discrimination controversies
Electrical utility
Endangered wildlife
Environmental controversies
EU sanctions list
Factory farming
Fast food
Firearms
Food commodity derivatives
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Health-related controversies
Human rights controversies
Human trafficking
ILO Conventions
Interest-based products
Interest-bearing debt
Interest-bearing securities
Iran
Land use and biodiversity
Military contracting
Misleading communication
Modern slavery
Music
Myanmar
Non-sustainable palm oil
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
OECD Guidelines
Oil and gas
Opioid controversies
Oppressive governments
Palestinian human rights
Pharma controversies
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Pro-life
Russia
Single-use plastic
Stem cell research
Sudan
Sugar
Syria
Tar sands
Thermal coal
Tobacco
Tobacco - GICS
UK sanctions list
Undermining US elections
UN Global Compact
UN Guiding Principles
US OFAC sanctions list
Weapons

Impact trend

Change in rating for overall impact

Log in to view this information

Company

Employees

Sector

Health Care

Industry

Biotechnology

Sub-industry

Biotechnology

SASB industry

Biotechnology & Pharmaceuticals

Headquarters

Israel

Share classes

RDHL

More info

https://www.redhillbio.com

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates that are in clinical development. These include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection, and host-directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204, which is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Material causes

Ethos considers the following causes material for Redhill Biopharma, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

Access to affordable healthcare

Ensure universal access to affordable, quality healthcare

Accountable institutions

Build accountable and inclusive institutions at all levels

Child and maternal health

End preventable deaths of mothers and children, support reproductive health everywhere

Decent, safe work opportunities

Promote full and productive employment for all, in safe work environments

Disaster readiness and effective aid

Be prepared for natural disasters and provide effective aid when disasters happen

Disease eradication

Eradicate infectious and non-communicable diseases